Deposition of amyloid-beta (Abeta) protein in the brain has been postulated to be the cause of Alzheimer's disease (AD). However, the finding of post-mortem amyloid plaque deposition in the brains of individuals in whom the absence of clinical AD was well-documented prior to their death has been variably interpreted to both support and refute this hypothesis. This wide range of interpretations is partly due to the lack of in vivo longitudinal data on the natural history of amyloid deposition in persons who do not show clinical symptoms of dementia. This proposal will assess in vivo evidence of brain amyloid deposition in """"""""normal"""""""" elderly subjects who do not meet clinical criteria for mild cognitive impairment (MCI) or AD. We refer to these subjects as """"""""clinically unimpaired"""""""". We will address three fundamental questions: 1) How common is amyloid deposition in clinically unimpaired elderly;2) Is the greater variability of cognitive performance in the clinically unimpaired elderly (compared to the young) explained by the presence or absence of amyloid deposition and 3) Will clinically unimpaired elderly who have evidence of amyloid deposition invariably progress to a clinical diagnosis of MCI or AD? Our group has developed an in vivo amyloid imaging positron emission tomography (PET) radiotracer termed """"""""Pittsburgh Compound-B"""""""" (PIB). We propose to use this new amyloid imaging technology to provide insight into the questions raised above. The proposed research will test the central hypotheses that amyloid deposition can be demonstrated in clinically unimpaired elderly, that amyloid deposition will correlate with common cognitive changes of """"""""normal aging"""""""" and both amyloid deposition and sub-clinical cognitive deficits will progress in tandem over time. With extended periods of observation that will begin in, but extend beyond this study, we hypothesize that this progression will lead to clinical AD. Subjects in their 60's, 70's and 80's will be screened to rule-out dementia using a standard """"""""diagnostic neuropsychological assessment"""""""". Clinically unimpaired subjects will be further tested, using well-established cognitive measures, to determine the presence of sub-clinical decrements in cognitive performance commonly found in """"""""normal aging"""""""". All subjects will receive PET imaging with PIB and FDG (the latter being the current standard for functional neuroimaging in AD). All assessments will be performed at baseline and 24 months. We will complete 24 month follow-up on 15 65-69 y/o, 25 75-79 y/o and 25 80-84 y/o subjects. Subjects identified as amyloid-positive at 24 months will be followed yearly in years four and five.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AG025516-05
Application #
7579841
Study Section
Clinical Neuroscience and Disease Study Section (CND)
Program Officer
Wagster, Molly V
Project Start
2005-03-01
Project End
2010-02-28
Budget Start
2009-04-01
Budget End
2010-02-28
Support Year
5
Fiscal Year
2009
Total Cost
$362,933
Indirect Cost
Name
University of Pittsburgh
Department
Psychiatry
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry :
Cohen, Ann D; McDade, Eric; Christian, Brad et al. (2018) Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. Alzheimers Dement 14:743-750
Nadkarni, Neelesh K; Lopez, Oscar L; Perera, Subashan et al. (2017) Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults. J Gerontol A Biol Sci Med Sci 72:431-437
Edelman, Kathryn; Tudorascu, Dana; Agudelo, Christian et al. (2017) Amyloid-Beta Deposition is Associated with Increased Medial Temporal Lobe Activation during Memory Encoding in the Cognitively Normal Elderly. Am J Geriatr Psychiatry 25:551-560
Hartley, Sigan L; Handen, Benjamin L; Devenny, Darlynne et al. (2017) Cognitive decline and brain amyloid-? accumulation across 3 years in adults with Down syndrome. Neurobiol Aging 58:68-76
Snitz, Beth E; Lopez, Oscar L; McDade, Eric et al. (2015) Amyloid-? Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. J Alzheimers Dis 48 Suppl 1:S151-9
Chen, Yin J; Rosario, Bedda L; Mowrey, Wenzhu et al. (2015) Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET. J Nucl Med 56:1199-205
Goodheart, A E; Tamburo, E; Minhas, D et al. (2015) Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities. Neuroimage Clin 9:479-83
Rabin, Laura A; Smart, Colette M; Crane, Paul K et al. (2015) Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. J Alzheimers Dis 48 Suppl 1:S63-86
Nunley, Karen A; Ryan, Christopher M; Orchard, Trevor J et al. (2015) White matter hyperintensities in middle-aged adults with childhood-onset type 1 diabetes. Neurology 84:2062-9

Showing the most recent 10 out of 75 publications